May 2024
1. FOX DA
   Rheumatoid arthritis - the challenge of heterogeneity.
   Curr Opin Rheumatol. 2024;36:201-202.
   

   >> Share

   
   
2. JOHNSON NM, Koumpouras F
   Chimeric antigen receptors: "CARs" in the fast lane for rheumatology.
   Curr Opin Rheumatol. 2024;36:176-183.
   

   >> Share

   
   March 2024
3. DEANE KD
   Rheumatoid arthritis: prediction of future clinically-apparent disease, and prevention.
   Curr Opin Rheumatol. 2024 Mar 6. doi: 10.1097/BOR.0000000000001013.
   

   >> Share

   
   
4. BARTH K, Gill H, Singh N
   Long-term safety of biologic and targeted synthetic disease modifying drugs in rheumatology.
   Curr Opin Rheumatol. 2024;36:113-119.
   

   >> Share

   
   February 2024
5. STEINER G, Toes REM
   Autoantibodies in rheumatoid arthritis - rheumatoid factor, anticitrullinated protein antibodies and beyond.
   Curr Opin Rheumatol. 2024 Feb 27. doi: 10.1097/BOR.0000000000001006.
   

   >> Share

   
   
6. MYASOEDOVA E, Matteson EL
   Updates on interstitial lung disease and other selected extra-articular manifestations of rheumatoid arthritis.
   Curr Opin Rheumatol. 2024 Feb 26. doi: 10.1097/BOR.0000000000001007.
   

   >> Share

   
   
7. PARK E, Bathon J
   Cardiovascular complications of rheumatoid arthritis.
   Curr Opin Rheumatol. 2024 Feb 12. doi: 10.1097/BOR.0000000000001004.
   

   >> Share

   
   January 2024
8. WALLACE BI, Cooney L, Fox DA
   New molecular targets in the treatment of rheumatoid arthritis.
   Curr Opin Rheumatol. 2024 Jan 3. doi: 10.1097/BOR.0000000000001000.
   

   >> Share

   
   November 2023
9. COHEN S, Reddy V
   Janus kinase inhibitors: efficacy and safety.
   Curr Opin Rheumatol. 2023;35:429-434.
   

   >> Share

   
   September 2023
10. NEUMANN E, Heck C, Muller-Ladner U
    Recent developments in the synovial fibroblast pathobiology field in rheumatoid arthritis.
    Curr Opin Rheumatol. 2023 Sep 13. doi: 10.1097/BOR.0000000000000978.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share